Targeted inhibitors and antibody immunotherapies: Novel therapies for paediatric leukaemia and lymphoma

Keyphrases

• Acute Myeloid Leukemia 100%
• Anaplastic Large Cell Lymphoma 50%
• Anaplastic Lymphoma Kinase-positive 50%
• Antibody Targeting 50%
• Antibody-based Immunotherapy 100%
• Antibody-drug Conjugate 50%
• B-cell Lymphoma 2 (Bcl-2) 50%
• BCP-ALL 50%
• BCR-ABL Positive 50%
• Bispecific 50%
• Blinatumomab 50%
• Bruton's Tyrosine Kinase 50%
• CD123 50%
• CD19 50%
• CD22 50%
• CD38 50%
• Cell Therapy 50%
• Cellular Pathways 50%
• Childhood Leukemia 50%
• Cure Rate 50%
• Cyclin-dependent Kinase 4 (CDK4) 50%
• Cyclin-dependent Kinase 6 (CDK6) 50%
• Dismal Prognosis 50%
• Drug Development 100%
• Evidence Needs 50%
• FLT3-ITD 50%
• Gemtuzumab Ozogamicin 50%
• Genetic Subtypes 50%
• Improved Outcomes 50%
• International Collaboration 50%
• JAK-STAT 50%
• KMT2A 50%
• KMT2A-rearranged Leukemia 50%
• Lag behind 50%
• Less Toxic 50%
• Leukemia Therapy 50%
• Leukemia-lymphoma 50%
• Lymphoma 50%
• Lymphoma Therapy 50%
• Medical Needs 50%
• Medicinal Products 50%
• Menin Inhibitors 50%
• New Agents 50%
• Newly Diagnosed 50%
• Novel Agents 50%
• Novel Therapies 100%
• Oncology 50%
• Pediatric Cancer 100%
• Pediatric Leukemia 100%
• Pediatric Lymphoma 100%
• Relapsed Disease 50%
• Relapsed or Refractory 50%
• Small Molecules 50%
• T-cell Acute Lymphoblastic Leukemia (T-ALL) 50%
• Targeted Inhibition 50%
• Targeted Inhibitors 100%
• Targeted Therapy 100%
• Targeting Antibodies 100%
• Therapeutic Potential 100%

Medicine and Dentistry

• Acute Lymphoblastic Leukemia 25%
• Acute Myeloid Leukemia 50%
• Anaplastic Large Cell Lymphoma 25%
• Anaplastic Lymphoma Kinase 25%
• B Cell 25%
• Blinatumomab 25%
• Bruton Tyrosine Kinase 25%
• Cell Therapy 25%
• Conjugate 25%
• Disease 50%
• Immunotherapy 100%
• Inotuzumab Ozogamicin 25%
• Leukemia 100%
• Methionine 25%
• Oncology 25%
• Pediatric Cancer 50%
• Pediatrics 100%
• Precursor 25%
• Targeted Therapy 50%